Table 1. Baseline characteristics.
| Baseline characteristic | Active UC (n = 10) | Inactive UC (n = 7) | Active CDc (n = 5) | IC (n = 5) | Controls (n = 10) | p-value |
| Male/female (%) | 6/4 (60.0/40.0) | 4/3 (57.1/42.9) | 2/3 (40.0/60.0) | 1/4 (20.0/80.0) | 5/5 (50.0/50.0) | 0.64 |
| Median (IQR) age (years) | 55.0 (45.3–61.3) | 51.1 (36.1–60.4) | 45.9 (36.1–60.1) | 69.1 (68.2–78.4) | 57.7 (51.9–62.6) | 0.35 |
| Median (IQR) BMI | 27.3 (23.1–29.7) | 26.0 (22.7–26.5) | 27.1 (20.2–30.4) | 21.5 (19.7–22.1) | 26.3 (22.4–29.4) | 0.46 |
| Median (IQR) duration of disease (years) | 7.1 (0.6–20.1) | 6.6 (4.0–14.4) | 9.8 (7.6–15.0) | NA | NA | 0.94 |
| Extent of disease | ||||||
| left-sided colitis (%) | 9 (90.0) | 6 (85.7) | NA | NA | NA | 1 |
| pancolitis (%) | 1 (10.0) | 1 (14.3) | NA | NA | NA | 1 |
| colitis (%) | NA | NA | 4 (80.0) | NA | NA | NA |
| ileo-colitis (%) | NA | NA | 1 (20.0) | NA | NA | NA |
| Median (IQR) C-reactive protein (mg/dL) | 4.1 (2.6–16.2) | 1.6 (0.6–2.9) | 2.9 (1.5–5.7) | 6.1 (5.5–13.2) | NA | 0.54 |
| Concomitant medication | ||||||
| 5-Aminosalicylates (%) | 9 (90.0) | 5 (71.4) | 3 (60.0) | NA | NA | 0.39 |
| Corticosteroids (%) | 4 (40.0) | 0 (0.0) | 2 (40.0) | NA | NA | 0.15 |
| Azathioprine (%) | 0 (0.0) | 1 (14.3) | 0 (0) | NA | NA | 0.30 |
| Methotrexate (%) | 0 (0.0) | 0 (0.0) | 1 (20.0) | NA | NA | 0.17 |
| Biologics (%) | 1 (10.0) | 0 (0.0) | 0 (0) | NA | NA | 0.53 |
| Active smoking (%) | 1 (10.0) | 2 (42.9) | 1 (20.0) | 1 (20.0) | NA | 0.81 |
| Average (SD) total Mayo score | 8 (±1.5) | 0 (±0.5) | NA | NA | NA | 0.001 |
| Median (IQR) histological Geboes score | 5.2 (4.1–5.3) | 0.0 (0.0–0.1) | NA | NA | NA | <0.001 |
IQR: interquartile range; BMI: body mass index; SD: standard deviation.